Reata Pharmaceuticals — Investor Presentation (January 2021)
53 slides from Reata Pharmaceuticals's investor presentation, Jan 11, 2021
Slide 1: Investor Presentation January 2021
Investor Presentation JANUARY 2021 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement
Slide 3: Reata at a Glance
Reata at a Glance CKD1 Pipeline Positive Phase 3 data for bardoxolone in Alport syndrome NDA filing planned for 1Q21 Pipeline in rare forms of CKD including the ongoing Phase 3 FALCON study in ADPKD Neurology Pipeline Plan to initiate 2nd pivotal study of omaveloxolone in FA in 2H21, following discu
Slide 4: Extensive Pipeline in Chronic Kidney Disease and Neurology
Extensive Pipeline in Chronic Kidney Disease and Neurology Autoimmune Indications | RTA 1701 CKD Caused by Alport Syndrome | Bardoxolone* IgA Nephropathy | Bardoxolone Type 1 Diabetic CKD | Bardoxolone Focal Segmental Glomerulosclerosis | Bardoxolone Autosomal Dominant Polycystic Kidney Disease | Ba
Slide 5: Key 2021 Goals
Key 2021 Goals CKD Caused by ADPKD | Bardoxolone Continued enrollment in Phase 3 FALCON study Submit NDA in 1Q21 If designated as priority review, PDUFA expected in 4Q21 Submit MAA in 4Q21 CKD Caused by Alport Syndrome | Bardoxolone Plan to initiate Phase 2 study in 1Q21 Data expected 2H21 Fast Prog
Slide 6: Chronic Kidney Disease Pipeline
Chronic Kidney Disease Pipeline
Slide 7: Bardoxolone Activates Nrf2 to Restore Mitochondrial Function
Bardoxolone Activates Nrf2 to Restore Mitochondrial Function and to Suppress Inflammatory and Fibrotic Processes Through Nrf2, bardoxolone promotes the restoration of mitochondrial function, the reduction of oxidative stress, and the inhibition of NF-κB and inflammatory signaling A recent human geno
Slide 8: Bardoxolone Currently in Development for Rare Forms of CKD
Bardoxolone Currently in Development for Rare Forms of CKD Significant opportunity in rare forms of CKD We estimate aggregate prevalence exceeds 700,000 patients in the U.S. Similar prevalence of each disease in EU5 region Few or no effective therapies currently approved CARDINAL Phase 3 study in Al
Slide 9: Bardoxolone U.S. Commercial Opportunity
Bardoxolone U.S. Commercial Opportunity 9 1Alport Syndrome Foundation and estimates based on Persson Clin Nephrol (2005), USRDS Report, Hasstedt Am J Hum Genet (1983), Temme, Kidney Int (2012); 2Projected diagnosed patients with CKD1-5 in the U.S., April 2020 IQVIA claims analysis; 3USRDS,4Jais et.a
Slide 10: Bardoxolone in Alport Syndrome
Bardoxolone in Alport Syndrome
Slide 11: Alport Syndrome Background
1Kruegel et al., Nat Rev Nephrol (2013), Gomez et al., JCI (2015); 2Groopman et al. N Engl J Med. 2019; 3Kashtan et al., Kidney Int (2018); 4Jais et al., JASN (2000); 5NKF-ASF-FDA Voice of the Patient Externally Led Patient-Focused Drug Development Meeting on Alport Syndrome, August 3, 2018; 6CARDIN
Slide 12: CARDINAL Phase 3 Study Design
CARDINAL Phase 3 Study Design Primary Endpoints: on-treatment change from baseline in eGFR vs. placebo at Week 48 and Week 100 Key Secondary Endpoint: off-treatment change from baseline in eGFR vs. placebo at Week 52 and Week 104 (4 weeks after withdrawal of drug) International, randomized, double-b
Slide 13: CARDINAL Phase 3 Disposition
CARDINAL Phase 3 Disposition KEYWORD Discontinuations for bardoxolone patients were higher than the placebo No more than two discontinuations due to any one AE Approximately half of imbalance was due to management of aminotransferase increases 98% of patients completed follow-up through Week 104 13
Slide 14: CARDINAL Phase 3: Met Year 1 Primary and Key Secondary Endpoints
CARDINAL Phase 3: Met Year 2 Primary and Key Secondary Endpoints Mean ± SEM eGFR Change (mL/min) Randomization was stratified by baseline UACR category (≤300 mg/g; >300 to 1000 mg/g; >1000 to 3500 mg/g). The difference between Bard and placebo is estimated using a model with baseline eGFR, UACR stra
Slide 15: Trajectory of On-treatment eGFR Shows Separation with Continued Treatment
Bardoxolone continued to increase eGFR in second year of treatment ITT population, which includes patients who were off drug for over one year, shows separation through Week 100 mITT analysis demonstrates larger effect since only eGFR values from patients who remained on treatment were included Traj
Slide 16: Continued Increases in eGFR Maintained Through 3 Years in EAGLE
Open-label extended-access study represents three years of bardoxolone treatment Mean eGFR increases after 2- and 3- years of treatment suggest continued separation over time Continued Increases in eGFR Maintained Through 3 Years in EAGLE Extension Study Data in table are observed mean ± SD changes
Slide 17: Bardoxolone Reduced Risk of Kidney Failure Event Composite
CARDINAL Phase 3: Bardoxolone Reduced Risk of Kidney Failure Event Composite Hazard ratio=0.49 p=0.086 Probability of No Event Bardoxolone reduced the risk by 50% of a kidney failure event composite defined as: ESKD, Confirmed 30% eGFR decline, or Confirmed eGFR < 15 mL/min 17
Slide 18: Significant Treatment Effect Observed in Pediatric Patients
Significant Treatment Effect Observed in Pediatric Patients eGFR Change from Baseline Mean± SEM, mL/min Placebo Bardoxolone Week 100 and Week 104 eGFR changes for pediatric subpopulation analyzed using the same methodologies described for overall ITT population p=0.004 p=0.017 Mean ± SEM eGFR Change
Slide 19: No Changes in Blood Pressure or Fluid-Overload Adverse Events
No Changes in Blood Pressure or Imbalances in Fluid-Overload Adverse Events Blood pressure, a sensitive measure of fluid status, was unchanged relative to placebo No imbalances in AEs associated with fluid status, including hypertension or peripheral edema No SAEs of fluid-overload in patients treat
Slide 20: UACR Not Increased Relative to Placebo at Year 2
UACR Not Increased Relative to Placebo at Year 2 Early UACR increases accounted for by eGFR increases UACR not significantly different than placebo at Weeks 100 and 104 Geometric Mean UACR Over Time Geometric Mean ± SEM UACR (mg/g) 20
Slide 21: Adverse Event Overview
Adverse Event Overview No Deaths SAEs in patients treated with bardoxolone: Approximately half the rate of placebo No fluid overload or cardiac events None reported in pediatric patients Discontinuation due to AEs higher in patients treated with bardoxolone No imbalances in other AE categories of in
Slide 22: Adverse Events Reported in >10% of Patients
Adverse Events Reported in > 10% of Patients AE profile consistent with prior trials Majority of AEs were mild or moderate Anticipated AEs likely related to pharmacology of drug1,2 Muscle spasms: not associated with evidence of muscle injury ALT and AST increases: no cases of Hy’s Law or other evide
Slide 23: Safety Summary
Safety Summary AE Profile is consistent with prior trials Majority of AEs were mild to moderate in severity Approximately 50% fewer bardoxolone patients reported SAEs UACR not increased relative to placebo after two years Fewer non-kidney AEs associated with Alport in bardoxolone patients Changes in
Slide 24: Alport Syndrome Program Summary
Primary and key secondary efficacy endpoints were met at Year 1 and Year 2 Plan to submit NDA in first quarter of 2021 In the EAGLE long-term extension study, increases in eGFR from baseline observed after 1 year of treatment were sustained on average for 3 years Bardoxolone had favorable safety pro
Slide 25: Identifying Patients with Alport Syndrome
: Identifying Patients with Alport Syndrome 1Groopman et al. N Engl J Med. 2019; 2Cameron-Christie JASN 2019; Malone et al. Kidney International 2014; Gast Nephrol Dial Transplant 2016; Xie Journal of Molecular Cell Biology 2014; Devarajan et.al. ASN Kidney Week, 2020 Misdiagnosis rate reported to b
Slide 26: Preparation for Launch Success
Disease Awareness Market Research Product Access & Health Economics Operational Readiness Reata has all necessary people, processes and systems in place to support a successful launch Preparation for Launch Success 2021 Commercial Readiness Goals Physicians, patients, and payers recognize AS, burden
Slide 27: Bardoxolone in ADPKD
Bardoxolone in ADPKD
Slide 28: ADPKD Background
1Bergmann et.al. Nat Rev Dis Primers. 2018; 2Podrini et.al. Cell Signal. 2020; 3NIH – About Autosomal Dominant Polycystic Kidney Disease (link), Willey et.al Kidney Dis 2019; 4What is ADPKD? Polycystic Kidney Disease Foundation (link); 5Torres et.al. N Engl J Med. 2017, Rastogi et.al. Ther Clin Risk
Slide 29: FALCON Phase 3 Study of Bardoxolone in ADPKD
FALCON Phase 3 Study of Bardoxolone in ADPKD Phase 3 similar in design to CARDINAL with two-year treatment duration Planning to enroll approximately 300 patients across approximately 100 sites in the U.S., Europe, Australia, and Japan eGFR 30-90 mL/min Age 18-70 years old Primary Endpoints: off-
Slide 30: ADPKD Cohort of PHOENIX
ADPKD Cohort of PHOENIX The ADPKD cohort of the PHOENIX Phase 2 study of bardoxolone in patients with rare forms of CKD enrolled 31 patients Average annual loss of eGFR of -4.8 mL/min prior to study entry based on historical eGFR data from 3 years prior to enrollment for 29 of 31 patients Statistica
Slide 31: Slide 31
Slide 32: Omaveloxolone in Friedreich's ataxia
Omaveloxolone in Friedreich’s ataxia
Slide 33: Friedreich's Ataxia Background
1Cook and Giunti, Br. Med. Bull. 2017; 2Patel et. al. Ann. Clin. Transl. Neurol. 2016 Friedreich’s Ataxia Background 33
Slide 34: MOXIe Part 2 Study Design
MOXIe Part 2 Study Design International, double-blind, placebo-controlled, randomized, registrational trial (n=103) Enrolled a wide and representative range of patients with FA Baseline mFARS: 20 to 80 Age: 16 to 40 years Patients randomized 1:1 to 150 mg omaveloxolone or placebo 48 week treatment d
Slide 35: MOXIe Part 2 Met its Primary Endpoint
MOXIe Part 2 Met its Primary Endpoint Omaveloxolone treatment significantly improved mFARS by -2.40 points relative to placebo in the primary analysis population at Week 48 (n=82; p=0.014) Improvement was time-dependent 35
Slide 36: MOXIe Part 2: mFARS Outcomes Favored Omaveloxolone in Subgroups
MOXIe Part 2: mFARS Outcomes Favored Omaveloxolone Over Placebo in Major Subgroups and All Analysis Populations Favors Placebo Favors Omav 36
Slide 37: MOXIe Part 2: Omaveloxolone Improved Activities of Daily Living
MOXIe Part 2: Omaveloxolone Improved Activities of Daily Living FA-ADL assessed in pivotal MOXIe part 2 While alpha was not preserved in the hierarchy, omaveloxolone nominally improved FA-ADL All nine questions numerically favored omaveloxolone On average, omaveloxolone-treated patients did not prog
Slide 38: MOXIe Part 2: Summary of Efficacy
MOXIe Part 2: Summary of Efficacy at Week 48 Omaveloxolone improved several other efficacy measures assessed as secondary endpoints PGIC was first secondary in the hierarchy and numerically improved with a p-value of 0.10 Alpha was not preserved, and all other tests were descriptive Some measures ar
Slide 39: MOXIe Part 2: Summary of Safety
MOXIe Part 2: Summary of Safety 1Lewis J et al., Clin Transl Sci (2020) Adverse events (AEs) generally mild to moderate in intensity 4 omaveloxolone-treated patients (8%) and 2 placebo-treated patients (4%) discontinued study due to AEs ALT and AST increases may be related to the pharmacological act
Slide 40: Baseline-Controlled Study: Objective and Design
Baseline-Controlled Study: Objective and Design Baseline-controlled study (cross-over study) assessed the strength and certainty of the positive primary endpoint findings in MOXIe Part 2 Treatment-naïve patients from MOXIe Part 1 and Part 2 served as their own controls to assess changes in mFARS in
Slide 41: Baseline-Controlled Study: mFARS Results
Baseline-Controlled Study: mFARS Results Demonstrate Significance Across All Analysis Populations Pre-specified test of paired differences between Part 1 and Part 2 populations showed no difference (p=0.53), confirming suitability of pooling Primary Analysis: -3.76 improvement in mFARS (p-value=0.00
Slide 42: Omaveloxolone Regulatory Update
Omaveloxolone Regulatory Update FDA has provided guidance that it is not concerned about the reliability of the mFARS primary endpoint results in the MOXIe Part 2 study, but is not convinced that the results are sufficient to support a single study approval Results of the baseline-controlled study a
Slide 43: Friedreich's Ataxia Program Summary
cycle Friedreich’s ataxia is a rare, severe disease with no approved therapies MOXIe Part 2 demonstrated a time-dependent PBO-corrected improvement in mFARS. At week 48, it showed a PBO-corrected 2.40 point mean improvement Baseline-Controlled Study met its primary endpoint of paired difference of 3
Slide 44: Omaveloxolone Pharmacology May Be Applicable to Broad Neurological Diseases
Omaveloxolone Pharmacology May Be Applicable to a Broad Set of Neurological Diseases Yang et al., PLoS One (2009); Neymotin et al., Free Rad Bio (2011); Dinkova-Kostova et al., (2015); Stack et al., Free Rad Biol Med 49 (2010); Dumont et al., J Neurochem (2009); Kim et al., Cells (2019) Shekh-Ahmad,
Slide 45: RTA 901 Hsp90 Modulator for Diabetic Neuropathy
RTA 901 Hsp90 Modulator for Diabetic Neuropathy
Slide 46: RTA 901 in Diabetic Peripheral Neuropathic Pain
RTA 901 in Diabetic Peripheral Neuropathic Pain Overview of diabetic peripheral neuropathic pain (DPNP) in the U.S. Overall prevalence of roughly 4 million patients with moderate or severe DPNP1-3 Estimated 2 million adult patients diagnosed with DPNP seek treatment annually2 Currently approved medi
Slide 47: RTA 901: Hsp90 Modulator for Neurological Indications
RTA 901: Hsp90 Modulator for Neurological Indications RTA 901 is a highly potent and selective, oral, small molecule C-terminal modulator of Hsp90 Hsp90 inhibition disrupts Hsp90-HSF1 complex leading to increased transcription of cytoprotective and molecular chaperone genes including Hsp70 Induction
Slide 48: RTA 901 Rapidly Reverses Hyperalgesia and Insensate Neuropathy in Animal Models
RTA 901 Rapidly Reverses Hyperalgesia and Insensate Neuropathy in Animal Models RTA 901 treatment in rat model of type 1 diabetic neuropathic pain demonstrated dose-dependent suppression of hypersensitivity a day after initiation of treatment that was sustained Once-daily oral RTA 901 reverses loss
Slide 49: RTA 901 Phase 1 Study Demonstrated Acceptable PK Profile
RTA 901 Phase 1 Study Demonstrated an Acceptable PK Profile with No Safety or Tolerability Concerns Phase 1 SAD/MAD trial of oral, once-daily RTA 901 in healthy volunteers PK was linear up to the highest doses evaluated with a half-life ranging from 2-9 hours Exposures easily achievable in 10-fold e
Slide 50: Operations, Financials, Intellectual Property
Operations, Financials, Intellectual Property
Slide 51: Financial Update
Financial Update Current cash balance of $578.3 million as of September 30, 2020* Based on our operational plans, we anticipate cash runway through mid 2024 *Excludes the estimated net proceeds of $277.4 million raised in December 2020 51
Slide 52: Reata Patent Portfolio
Reata Patent Portfolio Morphic form patent (US 8,088,824) claims commercial (amorphous) forms of bardoxolone Claims granted in U.S., EU, Japan, Canada, China, Mexico, Eurasia, and 9 other territories, with applications pending in 8 countries Anticipated protection to 2034 in U.S. and 2033 in rest of
Slide 53: List of Abbreviations
List of Abbreviations 25FwT 9-HPT ARP. ACEI ‘ADPKD AE/AES ALT ARB aS AST ATP Bardoxolone emi BNP BP caic KD covio-19 or PNP. eGFR ESKO EUS. FA FAADL FDA FSGS 25-foot walk test S-hole peg test All Randomized Population Angiotensin-converting enzyme inhibitors ‘Autosomal dominant polyeystic kidney dis
Reata Pharmaceuticals — Investor Presentation (January 2021) on 6ix